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Cell division autoantigen 1 (CDA1) modulates cell
proliferation and transforming growth factor-b (TGF-b)
signaling in a number of cellular systems; here we found that
its levels were elevated in the kidneys of two animal models
of diabetic renal disease. The localization of CDA1
to tubular cells and podocytes in human kidney sections
was similar to that seen in the rodent models. CDA1 small
interfering RNA knockdown markedly attenuated, whereas
its overexpression increased TGF-b signaling, modulating
the expression of TGF-b, TGF-b receptors, connective tissue
growth factor, collagen types I, III, IV, and fibronectin genes
in HK-2 cells. CDA1 and TGF-b together were synergistic
in stimulating TGF-b signaling and target gene expression.
CDA1 knockdown effectively blocked TGF-b-stimulated
expression of collagen genes. This was due to its ability to
modulate the TGF-b type I, but not the type II, receptor,
leading to increased phosphorylation of Smad3 and
extracellular signal-regulated kinase mitogen-activated
protein kinase. Furthermore, the Smad3 inhibitor, SIS3,
markedly attenuated the activities of CDA1 in stimulating
TGF-b signaling as well as gene expression of collagens I,
III, and IV. Thus, our in vitro and in vivo findings show that
CDA1 has a critical role in TGF-b signaling in the kidney.
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Accumulation of extracellular matrix (ECM) has a pivotal role in
the development of diabetic nephropathy.1,2 A range of pathways
have been implicated in promoting ECM accumulation in
progressive renal disorders with the most widely studied,
involving transforming growth factor-b (TGF-b), a growth
factor that promotes fibrosis via specific intracellular signaling
molecules, known as Smads.3,4 Diabetic nephropathy has clearly
been shown to be at least partly TGF-b dependent and
attenuated by anti-TGF-b strategies.5–7 Furthermore, TGF-b, in
addition to other related cytokines such as connective tissue
growth factor (CTGF), appears to be a key factor in this process.8
Cell division autoantigen 1 (CDA1) has been initially shown
to arrest growth of HeLa cells.9 This antiproliferative effect
of CDA1 is attributed to the transcriptional upregulation of
cyclin-dependent kinase inhibitor protein p21Waf1/Cip1 (p21) via
p53 and extracellular signal-regulated kinase (ERK) mitogen-
activated protein kinase pathways.10 Both ERK and p53 are
known to be involved in TGF-b signaling in regulating p21 gene
expression.11–15 Indeed, ERK has been shown to be activated by
TGF-b via the dual specificity kinase activities of TGF-b type I
receptor (TbRI).14 Furthermore, p53 forms a complex with
activated Smads and brings the activated Smads to the proximity
of the target gene promoter.15 CDA1, also known as differentially
expressed nucleolar TGF-b target, is reported to be stimulated by
TGF-b.16 Indeed, we have recently shown that CDA1 modulates
TGF-b signaling in mouse vascular smooth muscle cells and
potentially has a role in diabetes-accelerated atherosclerosis.17
In this report, we have specifically examined the potential role
of CDA1 in the kidney as it pertains specifically to renal ECM
accumulation. Indeed, CDA1 modulates the TbRI, resulting in
amplification of the TGF-b signal, leading to an increase in the
production of ECM proteins in human renal proximal tubule cells.
RESULTS
In vivo studies
CDA1 expression increases in experimental diabetic nephro-
pathy. The spontaneously hypertensive rats (SHRs) with
diabetes for 32 weeks had lower body weight and higher
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HbA1c levels than their age-matched non-diabetic controls
(Table 1). However, systolic blood pressure was slightly lower
in the diabetic rats. The diabetic SHR had an increased
kidney weight, a higher kidney/body weight ratio, increased
urinary albumin excretion, increased daily urine volume,
and a greater renal tubular injury index. These data reflected
the renal damage in these diabetic rats. Indeed, Masson’s
Trichrome staining showed increased ECM in the kidney
from diabetic SHR (Figure 1a), which was associated with
the increased a-smooth muscle actin staining (Figure 1b).
The mRNA levels for TGF-b, TbRI, and TGF-b type II
receptor (TbRII) were significantly increased two- to fourfold
in diabetic rat kidneys, and the TGF-b target genes such
as CTGF and ECM genes, such as collagens I, III, IV, and
fibronectin were significantly increased two- to sixfold
(Figure 1c).
CDA1 was found to be located to tubular cells and
glomerular podocytes within the SHR kidney by immuno-
histochemical (IHC) staining (Figure 2a). The staining
was removed by preabsorption of the antibody with the
antigen, demonstrating the specificity of the antibody used
(Figure 2a). Furthermore, CDA1 protein levels, as deter-
mined by IHC staining (Figure 2b), and mRNA levels, as
determined by real-time PCR (Figure 2c), were significantly
higher in the diabetic SHR kidneys.
To complement the findings in diabetic rats, we examined
another model of diabetic nephropathy, the ApoE/ mouse,
which also demonstrated metabolic features of diabetes
including lower body weight, higher plasma glucose
and HbA1c levels, increased urine volume and increased
Table 1 |Metabolic and blood pressure data for
spontaneously hypertensive rats (SHRs)
Variable Non-diabetic (n=7) Diabetic (n=9)
HbA1c (%) 3.9±0.2 7.7±1.2
a
Body weight (g) 433.7±11.1 353.0±8.8b
Right kidney weight (g) 1.4±0.03 1.57±0.04b
Kidney weight/body weight (%) 0.31±0.01 0.44±0.01b
Albuminuria (mg/day) 6.9±1.0 57.7±13.1a
Urine volume (ml/day) 17.9±1.6 71.6±9.3b
Tubular injury index 0.26±0.03 0.56±0.1a
Systolic blood pressure (mmHg) 222.0±3.8 195.6±8.7a
Data are shown as mean±s.e.m.
aPo0.001.
bPo0.05 vs non-diabetic SHR.
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Figure 1 |Diabetes induces renal fibrosis in spontaneous
hypertensive rats (SHR). (a and b) Paraffin-embedded kidney
sections of SHR with streptozotocin-induced diabetes for 32
weeks (Dia) and age-matched non-diabetic control SHR (Con)
were stained by Masson’s Trichrome method to show extracellular
matrix (ECM) in blue color (a) and by immunohistochemical
staining using antibodies (1:1000 dilution) to a-smooth muscle
actin (a-SMA) to show a-SMA in brown color (b), with scale bars of
300mm shown (original magnification,  200). A negative control
with no primary antibody is shown for the immunohistochemical
staining of an SHR (Ab). Positive staining was quantified using
the Image-Pro Plus program. Approximately 10 random views
were measured per section to give an average arbitrary unit. A
graph of quantification is shown for ECM (a) and a-SMA (b) in
non-diabetic control (empty bar) and diabetic groups (solid bar).
(c) mRNA levels of the following proteins in the kidneys of
non-diabetic control (empty bar) and diabetic SHR groups
(solid bar) as determined by quantitative real-time reverse
transcription-PCR are shown: transforming growth factor (TGF)-b1
(TGFb), TGF-b type I receptor (TbRI), TGF-b type II receptor (TbRII),
connective tissue growth factor (CTGF), a-SMA, collagen I (COL1), III
(COL3), IV (COL4), and fibronectin (FN). Values are shown as
means±s.e. s.e. (n¼ 7 for control; n¼ 9 for diabetic group) is shown
as error bar. *Po0.05 and **Po0.001 vs non-diabetic control group.
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albuminuria (Table 2). As shown in Supplementary Figure S1
online, the diabetic ApoE/ mice had 43-fold increase in
renal CDA1 gene expression. There was also a B2- to 3-fold
increase in renal TbRI and TbRII mRNA levels. Indeed, in
these diabetic mouse kidneys, the fibrosis-associated genes such
as CTGF, collagen I, IV, and fibronectin were also upregulated
two- to threefold (Supplementary Figure S1 online).
CDA1 is expressed in human kidney. CDA1 was readily
detected in the human kidney, mainly localized to the tubules
and podocytes (Figure 3a), a staining pattern similar to that
observed in rodent kidneys (Figure 2a). Antibody specificity
was confirmed by preabsorption of the antibody with the
antigen, which removed the positive staining (Figure 3a),
a result consistent with that reported for rat kidney
(Figure 2a). The presence of CDA1 protein in human kidney
and in a human proximal tubule cell line HK-2 was
confirmed by western blotting with human lung tissue
serving as a positive control (Figure 3b). The transfected
HK-2 cells showed a Myc-tagged CDA1 (upper band,
Figure 3b) and the endogenous form of CDA1 (lower band,
Figure 3b), which was identical in molecular weight to the
CDA1 protein detected in human kidney and lung tissues.
The expression of CDA1 in podocytes was confirmed by
reverse transcription-PCR using a human podocyte cell
line with HK-2 serving as a control (Figure 3c).
In vitro studies
CDA1 overexpression increases and CDA1 knockdown
decreases expression of ECM genes. We used an adenoviral
construct (Ad-CDA1) to overexpress CDA1 in HK-2 cells, at
a low dose increasing CDA1 mRNA levels by46-fold and at
the high dose increasing by B80-fold (Figure 4a). As a
control, the vector control adenovirus (Ad-Con) had no
effect on CDA1 mRNA levels. As a result of the adenoviral-
delivered overexpression, CDA1 dose-dependently increased
the mRNA levels of TGF-b, CTGF, collagens I, III, and
fibronectin (Figure 4a). The CDA1 overexpression by the
Ad-CDA1 was confirmed by western blotting (see later).
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Figure 2 |Cell division autoantigen 1 (CDA1) expression levels
are increased in diabetic spontaneous hypertensive rat (SHR)
kidneys. CDA1 protein (a, b) was detected in SHR kidney sections
by immunohistochemical staining, and CDA1 mRNA levels
(c) were determined by quantitative real-time reverse
transcription-PCR. (a) CDA1 was stained in brown color mostly
in tubules (Ab), which was removed by preabsorption of the
antibody with antigen (AbþAg). Scale bar of 300 mm is shown
(original magnification,  200) for these two pictures. CDA1 was
also detected in podocytes (red arrow) within glomerulus (glo)
with a scale bar of 50 mm (original magnification,  400). (b) CDA1
was stained in the kidney sections of non-diabetic control (Con)
and 32-week diabetic (Dia) SHR and shown in brown color
(left panels). Scale bar of 600 mm is shown (original magnification,
 100). CDA1 staining was quantified (right panel) and analyzed
as described in the legend of Figure 1, and shown as arbitrary
units for the non-diabetic (empty bar) and diabetic groups
(solid bar). (c) CDA1 mRNA levels in the kidneys of non-diabetic
(empty bar) and diabetic groups (solid bar) are shown. Values are
means±s.e. s.e. (n¼ 7 for control; n¼ 9 for diabetic group) is
shown as error bar. zPo0.001 vs non-diabetic control group.
Table 2 |Metabolic data for ApoE/ mice
Variable Non-diabetic (n=8) Diabetic (n=6)
Plasma glucose (mmol/l) 7.3±0.48 30.7±1.86a
HbA1c (%) 4.1±0.16 13.2±0.82
a
Body weight (g) 29.6±0.83 23.8±0.71a
Albuminuria (mg/day) 0.052±0.01 0.13±0.02b
Urine volume (ml/day) 0.9±0.18 15.1±1.34a
Data are shown as mean±s.e.m.
aPo0.001.
bPo0.005 vs non-diabetic mice.
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To complement the findings with CDA1 overexpression,
HK-2 cells with 490% CDA1 knockdown by retroviral
expression of CDA1 small interfering RNA (siRNA) m957
resulted in a 490% decrease in mRNA levels for collagen I
and III, a420% decrease in fibronectin and440% decrease
in TGF-b (Figure 4b). The vector retrovirus transduced HK-2
cells did not change the mRNA levels of these genes. The
knockdown of CDA1 by the siRNA retrovirus was further
confirmed by western blotting (Figure 4c).
CDA1 knockdown attenuates TGF-b signaling. As TGF-b
regulates genes associated with ECM production and
accumulation via intracellular signaling, we determined the
role of CDA1 in modulating TGF-b signaling. TGF-b dose-
dependently stimulated the luciferase activities of the TGF-b
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Figure 3 |Cell division autoantigen 1 (CDA1) expression
in human kidney and proximal tubule cell line HK-2.
(a) Immunohistochemical staining of a human kidney section
showing CDA1 detected in both tubular cells and glomerular cells
(Ab) using anti-CDA1 antibody (1:1000 dilution), which was
removed by preabsorption of the antibody with antigen
(AbþAg). A scale bar of 300 mm is shown (original magnification,
 200). Staining of CDA1 in podocytes (red arrow) within the
glomerulus (glo) is shown with a scale bar of 50 mm (original
magnification,  400). (b) Western blot analysis showing CDA1 in
human kidney (K) and lung (L) tissue homogenates, and in the
human proximal tubule cell line HK-2 (HK2) transfected with
Myc-tagged CDA1 expressing plasmid. Blot was reprobed for
a-tubulin. (c) Reverse transcription-PCR detection of CDA1 mRNA
in podocytes. Total RNA isolated from a human podocyte cell
line (Pod)34 and from HK-2 cells as control (HK2) was reverse
transcribed using random primers and the synthesized
complementary DNA was used as a template for PCR using
a pair of CDA1-specific primers (forward primer: 50-CCGGAATTC
GAGGTGGTGATCATGGAAGAC-30; reverse primer: 50-ACGCGTCGA
CTCATCCTCTAGGTCAGAGTCG-30, underlined is sequence
identical to CDA1). The primers for b-actin are as follows: forward
primer 50-GAGGCCCAGAGCAAGAGAG-30 and reverse primer
50-GGCTGGGGTGTTGAAGGT-30. The PCR-amplified products at
the expected size of B800 bp for CDA1, 225 bp for b-actin,
and DNA standards (M) were shown after a 1.2% agarose gel
electrophoresis.
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Figure 4 |Transforming growth factor (TGF)-b, connective
tissue growth factor (CTGF), and extracellular matrix genes
are affected by alteration in cellular levels of cell division
autoantigen 1 (CDA1) in HK-2 cells. (a) HK-2 cells were infected
with no virus (white bars), control adenovirus at low dose
(B100 multiplicity of infection, MOI) (gray bars), and
CDA1-expressing adenovirus at low dose (B100 MOI) (hatched
bars) and high dose (B600 MOI) (black bars) for 24 h. mRNA levels
of specified proteins as determined by quantitative real-time
reverse transcription-PCR are shown as arbitrary units. Values are
means±s.e. s.e. (n¼ 6) is shown as error bar. *Po0.001 vs no virus
control and wPo0.001 vs low dose (100 MOI) CDA1-expressing
adenovirus group. (b) HK-2 cells were stably transduced with no
retrovirus (white bars), vector control retrovirus (gray bars), and
CDA1 siRNA m957 retrovirus (black bars). mRNA levels of these
cells were shown for proteins as specified. Values are means±s.e.
s.e. (n¼ 6) is shown as error bar. *Po0.001 and wPo0.05 vs no
virus control. (c) Western blot showing CDA1 and a-tubulin in
HK-2 cells stably transduced with no virus (NV), control retrovirus
(Vect), and CDA1 small interfering RNA (siRNA) m957 retrovirus
(siRNA). FN, fibronectin.
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responsive reporter construct, p3TP-Lux and the Smad3-
specific reporter construct, p(CAGA)12-Luc in the control
cells (Figure 5a). In the CDA1 siRNA retrovirus transduced
HK-2 cells, the stimulatory effect of TGF-b was markedly
attenuated by 460 and 480%, respectively (Figure 5a).
These findings demonstrate an important role for CDA1 in
TGF-b signaling, ultimately leading to the regulation of target
gene promoters.
CDA1 and TGF-b synergistically stimulate TGF-b signaling.
To demonstrate the ability of CDA1 to enhance TGF-b
signaling, we infected HK-2 cells with 3 doses of Ad-CDA1
for 24 h in order to overexpress CDA1 with Ad-Con as
controls. The cells were then treated with or without TGF-b
for a further 30 h. The similar cell density and percentage
of cells infected by the adenoviruses, which were green,
confirmed the comparable infection efficiency of both viruses
as shown in Supplementary Figure S2 online. Luciferase
activities of p3TP-Lux were stimulated49-fold by TGF-b in
control cells (Figure 5b). Ad-CDA1 alone in 3 increasing
doses stimulated the luciferase activities by 46-, 47-, and
411-fold, respectively (Figure 5b). The combination of TGF-b
treatment and CDA1 overexpression stimulated the luciferase
activities by 456-, 463-, and 467-fold, respectively,
depending on the Ad-CDA1 doses (Figure 5b). This result
clearly demonstrated a synergistic effect of CDA1 and TGF-b
in stimulating the TGF-b-responsive reporter activities.
CDA1 knockdown attenuates the profibrotic effect of
TGF-b. Consistent with the effect of CDA1 on TGF-b
signaling, we showed that CDA1 and TGF-b synergistically
stimulated the gene expression of collagens I and III, with
CDA1 knockdown sufficient to prevent TGF-b-stimulated
expression of these genes (Figure 6). Ad-CDA1 at 250 and
1000 multiplicity of infection, respectively, delivered a
progressive overexpression of CDA1 proteins in HK-2 cells,
whereas Ad-Con did not change the cellular level of CDA1
(Figure 6a). The two adenoviral constructs expressing siRNA
to target different regions of CDA1 mRNA resulted in
significant decreases in CDA1 protein levels (Figure 6b).
Using these adenoviral constructs to alter cellular levels of
CDA1 in HK-2 cells, we found that TGF-b treatment
moderately increased endogenous CDA1 mRNA levels
(Figure 6c). Ad-CDA1 increased CDA1 mRNA levels by
416-fold, which was further increased by TGF-b treatment.
Both CDA1 siRNA adenoviruses not only reduced the
endogenous CDA1 mRNA levels, but also prevented stimu-
lation of the CDA1 mRNA increase by TGF-b (Figure 6c).
Consistent with the alteration of the intracellular CDA1
levels, mRNA levels of collagens I and III were stimulated
by 44- or B5-fold by TGF-b alone in control cells, and by
B8- or B15-fold by CDA1 overexpression alone (Figure 6d
and e). The combination of CDA1 overexpression and TGF-b
treatment further increased the mRNA levels of collagens I
and III by up toB11- andB45-fold, respectively (Figure 6d
and e). Both siRNA adenoviral constructs effectively
prevented the TGF-b-induced stimulation of mRNA levels
for these genes (Figure 6d and e).
CDA1 enhances activation of Smad3 via TbRI. We investi-
gated the postulated molecular mechanisms responsible for
the action of CDA1 in modulating TGF-b signaling, using
our previously established CDA1 Tet-Off HeLa cells.9,10
We found that Smad3 phosphorylation increased when
the CDA1 level increased, with no effect on total Smad3
protein (Figure 7a). The activities of CDA1-induced
Smad3 activation were determined using p3TP-Lux and
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Figure 5 | Intracellular levels of cell division autoantigen 1
(CDA1) affect transforming growth factor (TGF-b) activity in
stimulating TGF-b-responsive reporter constructs in HK-2
cells. (a) HK-2 cells stably transduced with vector retrovirus (Con)
and retrovirus expressing CDA1 small interfering RNA (siRNA)
m957 (siR) were co-transfected with pGL3-BASIC, a promoter-less
luciferase plasmid (BASIC), p3TP-Lux (3TP), or p(CAGA)12-Luc
(CAGA) with a cytomegalovirus (CMV)-b-galactosidase plasmid by
electroporation as described previously.10 Approximately 24 h
after electroporation, the cells cultured in six-well plates were
treated with TGF-b at various concentrations for another 30 h.
TGF-b concentrations used are 0.00 (white bars), 0.05 (gray bars),
0.10 (hatched bars), and 0.20 ng/ml (black bars). Luciferase activity
was normalized against the b-galactosidase activity of each
sample. Values are means±s.e. s.e. (n¼ 6) is shown as error bar.
*Po0.001 vs no TGF-b treatment (0.00 ng/ml) within the same
group and wPo0.001 vs vector retrovirus transduced cells (Con)
treated with the same concentration of TGF-b. (b) HK-2 cells were
co-transfected with p3TP-Luc and CMV-galactosidase plasmids.
After 24 h culture, the cells were infected with a vector control
adenovirus (Ad-Con) and CDA1 expressing adenovirus (Ad-CDA1)
at, 0, 250, 500, and 1000 multiplicity of infection (MOI) for
24 h, and then treated without or with TGF-b at 0.2 ng/ml for
another 30 h. Luciferase activity was normalized against the
b-galactosidase activity of each sample. Values are means±s.e.
s.e. (n¼ 6) is shown as error bar. *Po0.001 vs no adenovirus and
no TGF-b treatment and wPo0.001 vs the same adenovirus dose
with no TGF-b treatment.
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p(CAGA)12-Luc. The luciferase activities of both constructs
were stimulated eight- and threefold, respectively, by CDA1
overexpression for 48 h (Figure 7b), a result consistent with
that observed in HK-2 cells (Figure 5b).
We have shown that CDA1 overexpression results in
activation of ERK mitogen-activated protein kinase path-
way,10 which is known to be activated by TbRI.14 We found
that the effects of CDA1 in activating both Smad3 (Figure 7c)
and ERK1/2 (Figure 7d) were inhibited by the TbRI inhibitor
SB431542, with Smad3 phosphorylation inhibited by
SB431542 in a dose-dependent manner. These results suggest
that the action of CDA1 in enhancing phosphorylation of
Smad3 and ERK1/2 is via TbRI.
Indeed, we found that TbRI, but not TbRII, was
upregulated at the mRNA level by CDA1, as determined
by real-time reverse transcription-PCR (Figure 7e and f).
This was shown with CDA1 overexpression in increasing
levels in HeLa cells by switching on the CDA1 transgene for
increasing time (Figure 7e) or by decreasing doxycycline
concentrations for 72 h (Figure 7f).
We carried out further experiments to confirm this role of
CDA1 in modulating TGF-b signaling in HK-2 cells. TGF-b
dose-dependently increased CDA1 protein levels in HK-2
cells (Figure 8a). Increased cellular levels of CDA1, delivered
by Ad-CDA1, resulted in increased Smad3 phosphorylation
(Figure 8b). Using the same antibody to phosphorylated
Smad3 as shown in CDA1 overexpressing HK-2 cells
(Figure 8b), the TGF-b-stimulated phosphorylation of Smad3
was detected in HK-2 cells, and, as expected, was inhibited by
the TbRI inhibitor SB431542 (Figure 8c). By contrast, the
TGF-b-stimulated Smad3 phosphorylation was enhanced by
increasing CDA1 protein levels in HK-2 cells delivered by Ad-
CDA1 at both low and high doses (Figure 8d).
The Smad3-specific inhibitor, SIS3, was used to specifi-
cally demonstrate a role for Smad3 in mediating the
profibrotic effect of CDA1. Adenoviral-delivered CDA1
overexpression resulted in Smad3 phosphorylation in HK-2
cells. SIS3 inhibited this phosphorylation of Smad3 at 1, 5,
and 10 mM in a dose-dependent manner (Figure 9a). This
CDA1 overexpression led to a 42.5-fold increase in the
mRNA level for TbRI, which was partially attenuated by SIS3,
at 1–10 mM (Figure 9b). CDA1 overexpression increased the
luciferase activities of p3TP-Lux, by 412-fold (Figure 9c)
and p(CAGA)12-Luc, by B20-fold (Figure 9d), which were
attenuated by SIS3 in a dose-dependent manner. Consistent
with these effects, there was a progressive decrease in gene
expression of the various collagens as a result of SIS3
treatment in a dose-dependent manner (Figure 9e–g).
DISCUSSION
In this study, we show a profibrotic role for CDA1, which
may be particularly relevant to diabetic nephropathy. This
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Figure 6 |Cell division autoantigen 1 (CDA1) overexpression enhances and CDA1 knockdown blocks the activity of transforming
growth factor (TGF)-b in stimulating expression of extracellular matrix genes. (a and b) Western blot analysis shows CDA1 and
a-tubulin in HK-2 cells infected by a control adenovirus (Ad-Con) and CDA1-expressing adenovirus (Ad-CDA1) at specified multiplicity of
infection (MOI) for 24 h followed by incubation in fresh medium for a further 30 h (a), or by adenoviruses expressing CDA1 small interfering
RNA (siRNA) m95710,16 or CDA1 siRNA 1562 (target sequence: 50-CAGCGAGAAUCCUGACCACAA-30) (b). (c–e) Five groups of HK-2 cells were
infected for 24 h with no virus (NV), control adenovirus (Con), CDA1-expressing adenovirus (CDA1), and adenoviruses expressing siRNA
m957 and 1562 to silence CDA1 (siRNA). These cells were then treated or not treated with TGF-b (0.2 ng/ml) for a further 30 h. Total RNA was
extracted and real-time PCR was performed to measure the relative mRNA levels for CDA1 (c), collagen III (d), and collagen I (e). Values
are means±s.e. s.e. (n¼ 6) is shown as error bar. *Po0.05 and zPo0.001 vs no TGF-b treatment; yPo0.05 and wPo0.001 vs HK-2 cells
with no virus and no TGF-b treatment, or with control adenovirus and no TGF-b treatment.
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affect TGF-b signaling in CDA1 Tet-Off HeLa cells. (a) CDA1 overexpression alone induces phosphorylation of Smad3. The CDA1 Tet-off
HeLa cells were cultured with decreasing concentrations of doxycycline as specified to regulate expression of the CDA1 transgene for 72 h.
Western blot analysis shows CDA1, phospho-Smad3 (Ser433/435) (p-Smad3), Smad2/3, and a-tubulin. (b) CDA1 enhances TGF-b-responsive
luciferase reporter activity. CDA1 Tet-off HeLa cells were co-transfected with the cytomegalovirus promoter-driven b-galactosidase
expression plasmid and the TGF-b-responsive luciferase reporter construct p3TP-Lux (3TP), or Smad3-specific reporter construct
p(CAGA)12-Luc ((CAGA)12). The cells were cultured in the absence of doxycycline to turn on, or in the presence of 5 ng/ml doxycycline
to turn off, the CDA1 transgene for 48 h. Luciferase activities normalized against the co-transfected b-galactosidase activities are shown as
fold induction by CDA1 overexpression (black bars) compared with control cells with the CDA1 transgene turned off (white bars). Values are
means±s.e. s.e. (n¼ 6) is shown as error bar. *Po0.001 vs CDA1 transgene turned off (white bars). (c and d) CDA1-induced phosphorylation
of Smad3 and ERK1/2(p44/42) is TbRI-dependent. The TbRI inhibitor, SB431542 (SB), was added to the CDA1 Tet-off HeLa cells at the
specified concentrations when doxycycline was withdrawn from the medium to turn on the CDA1 transgene (þ ), or when doxycycline
(5 ng/ml) was added to the medium to turn off the CDA1 transgene (), for 24 h. Western blots are shown for protein expression levels
of (c) CDA1, phospho-Smad3 (Ser435/455) (p-Smad3), Smad2/3, and GAPDH and (d) CDA1, phospho-ERK1/2(p44/42) (Thr202/Tyr204)
(p-ERK1/2), and total ERK1/2. (e and f) mRNA levels of CDA1 (left panels), TbRI (central panels), and TbRII (right panels) in CDA1 Tet-off HeLa
cells were determined by quantitative real-time reverse transcription-PCR. CDA1 transgene expression was either fully turned on by
doxycycline withdrawal for certain periods of time as specified (e), or regulated by doxycycline at various concentrations as specified
for 72 h (f). The mRNA levels relative to the cells with no CDA1 transgene expression, 0 h (e) or 5 ng/ml doxycycline (f) are shown as
fold changes. Values are means±s.e. s.e. (n¼ 6) is shown as error bar. *Po0.001 vs CDA1 transgene turned off.
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role of CDA1 appears to involve enhancing TGF-b signaling
pathway, leading to upregulation of renal ECM production.
Elevated CDA1 expression was observed in the kidneys
from two different models of experimental diabetes.
The appropriateness of these models has been extensively
evaluated18–21 with both models displaying some, if not most,
of the functional and structural characteristics of diabetic
nephropathy seen in man. With respect to the molecular
aspects of renal ECM accumulation, these rodents demon-
strate increased expression of TGF-b and TGF-b receptors,
Smad activation, and accumulation of various ECM
proteins.18,19 The concomitant increase in the expression
levels of CDA1 and molecules involved in TGF-b signaling
pathway in kidneys from the diabetic rodents implicates
CDA1 as having a role in these profibrotic processes in
diabetic nephropathy.
CDA1 was expressed in tubular cells from human kidney
(Figure 3a) and in the human proximal tubule cell line HK-2
(Figure 3b). Thus, in a series of in vitro studies we could
demonstrate using both siRNA and adenoviral strategies
to decrease or upregulate CDA1 expression, respectively, that
modulation of CDA1 levels led to a concomitant effect on
expression of the prosclerotic growth factor, CTGF, and a
range of ECM proteins including various collagens and
fibronectin.
It is known that the profibrotic effect of TGF-b is
mediated by signaling pathways including Smad and ERK
mitogen-activated protein kinase pathways.22–24 Consistent
with our view of the link between CDA1 and TGF-b, CDA1
knockdown markedly attenuated TGF-b-stimulated signaling
(Figure 5a). These studies demonstrated that CDA1 is
required for TGF-b to generate maximum signal to activate
the promoters of the target genes, and that Smad3 is involved
in this signaling process.
To further define this link between TGF-b and CDA1, we
identified a strong synergistic effect of CDA1 on TGF-b
signaling, as treating CDA1-overexpressing HK-2 cells with
TGF-b led to a further sevenfold increase in TGF-b signaling
(Figure 5b). The strong synergistic effect of CDA1 on TGF-b
in stimulating gene expression of ECM was also observed
in these HK-2 cells, which led to an B45- and B11-fold
increases in expression of both collagens I and III,
respectively (Figure 6). Furthermore, CDA1 knockdown by
two adenovirus constructs expressing siRNA species to target
different regions of CDA1 mRNA inhibited the stimulatory
effect of TGF-b in increasing expression of these collagen
genes. These findings raise the possibility that targeting
CDA1 in order to attenuate TGF-b activity may lead to
inhibition of the deleterious profibrotic effects of TGF-b,
the growth factor that is viewed as a major cause in the
development and progression of diabetic nephropathy.
The ability of CDA1 to enhance TGF-b signaling via
modulation of the TbRI was shown in both HeLa (Figure 7)
and HK-2 cells (Figure 8), consistent with the in vivo findings
that increases in renal CDA1 expression were associated
with an increase in TbRI mRNA levels in the kidneys for the
two different models of diabetic nephropathy (Figure 1c and
Supplementary Figure S1 online). First, the effect of CDA1 on
Smad3 phosphorylation in HeLa cells provides additional
information showing that this effect is not specific to the HK-
2 cell line, and that the link between CDA1 and Smad3
phosphorylation represents a mechanism that is widely
observed with respect to modulation of TGF-b signaling.
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Figure 8 |Adenovirus-delivered cell division autoantigen 1
(CDA1) overexpression in HK-2 cells resulted in Smad3
phosphorylation. (a) HK-2 cells were treated with transforming
growth factor (TGF)-b at specified concentrations for 30min.
Western blot analysis shows CDA1 and GAPDH as an appropriate
control for protein loading. (b) HK-2 cells were infected by a low
dose (250 multiplicity of infection, MOI) (L) or a high dose
(1000 MOI) (H) adenovirus, or by no virus (NV), for 24 h and then
the cells were cultured for a further 30 h in fresh medium. (c) HK-2
cells were untreated () or treated (þ ) with TGF-b at 0.2 ng/ml, or
with SB431542 at 2 mM (SB), or with vehicle dimethylsulfoxide for
30min, or pretreated with SB at 2 mM followed by TGF-b treatment
at 0.2 ng/ml for 30min. (d) HK-2 cells were infected by
a low dose (250 MOI) (L) or a high dose (1000 MOI) adenovirus,
or by no virus (NV), for 24 h and the cells were then untreated ()
or treated (þ ) with TGF-b at 0.2 ng/ml for a further 30 h. Western
blots show CDA1, phospho-Smad3 (pSmad3), total Smad3, and
b-actin or GAPDH.
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Second, as HeLa cells seem to have a higher level of Smad3,
this allows us to detect more readily Smad3 phosphorylation
by western blotting. Indeed, the use of a Smad3-specific
inhibitor, SIS3,25 was associated with attenuation of the
effects of CDA1 on luciferase activities of TGF-b-responsive
and Smad3-specific reporter constructs as well as reducing
expression of various TGF-b target genes.
The role of CDA1 in modulating TGF-b signaling and
ECM gene expression has been recently shown in mouse
vascular smooth muscle cells. Of direct relevance to those
in vitro findings, CDA1 expression was elevated in a murine
model of diabetes-accelerated atherosclerosis.17 Taking these
together, CDA1 seems to be an important molecule in
diabetic complications not only in diabetic nephropathy, but
also in other diabetic vascular complications, such as
atherosclerosis that also displays increased accumulation
of ECM.
CDA1 appears to be relevant to the nephropathic process
and in particular to renal ECM accumulation including in the
diabetic setting. This builds on a large body of data
implicating TGF-b and the TGF-b-dependent growth
factor, CTGF in promoting renal ECM accumulation.26–29
Approaches to inhibit TGF-b5,7,30,31 have been shown to
reduce progressive renal disease in various experimental
contexts including diabetic nephropathy. Furthermore, CTGF
appears to be an excellent target for reducing renal fibrosis,32
although the failure to develop specific non-peptidic
antagonists has reduced the enthusiasm for it being an
ongoing attractive target. Nevertheless, the ability of CDA1 to
modify CTGF expression (Figure 4a) further explains its
pivotal role in renal ECM accumulation. The advent of mice
with deletion of CDA1 and further exploration of CDA1 in
the human context should lead to a better understanding
of the role of CDA1 in the kidney, particularly in the context
of diabetes. Such studies will greatly assist in determining if
CDA1 is an appropriate target for developing new antifibrotic
strategies in progressive renal disorders, including diabetic
nephropathy.
Ad-CDA1
SIS3 (μM)
CDA1
p-Smad3
α-Tubulin
0 1 5 010
Ad-Con
*
* * *
: Ad-Con
: Ad-CDA1
: Ad-Con
: Ad-CDA1
: Ad-Con
: Ad-CDA1
: Ad-Con
: Ad-CDA1
: Ad-Con
: Ad-CDA1
: Ad-Con
: Ad-CDA1
p3
TP
-L
ux
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (×
 
10
,0
00
)
14
12
10
8
6
4
2
0
0 1 5 10
p(C
AG
A)
12
-
Lu
c
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (×
 1
0,
00
0)
25
20
15
10
5
0
0 1 5 10
SIS3 (μM) SIS3 (μM)
Tβ
R
I m
R
N
A 
(ar
ib
itr
a
ry
 u
ni
t)
CO
L 
l m
RN
A 
(ar
ib
itr
a
ry
 u
ni
t)
45
40
35
30
25
20
15
10
5
0
CO
L 
IV
 m
RN
A 
(ar
ib
itr
a
ry
 u
ni
t)
3
2.5
1.5
2
1
0.5
0
CO
L 
lll 
m
RN
A 
(ar
ib
itr
a
ry
 u
ni
t)
10
80
70
60
50
40
30
20
0
0 1 5 10
SIS3 (μM)
0 1 5 10
SIS3 (μM)
0 1 5 10
SIS3 (μM)
0 1 5 10
SIS3 (μM)
3.5
2
1.5
1
0.5
0
3
2.5
*
*
*
* *
*
*
*
*
*
**
*
*
*
*
*
*
Figure 9 | Effect of cell division autoantigen 1 (CDA1) on transforming growth factor (TGF)-b signaling and extracellular matrix
gene expression is dose-dependently inhibited by the Smad3 inhibitor, SIS3. HK-2 cells were infected by CDA1 expressing adenovirus
(Ad-CDA1) and a control adenovirus (Ad-Con) at 250 multiplicity of infection (MOI) in the presence of SIS3 at specified concentrations
for 24 h, washed with phosphate-buffered saline, and then incubated for a further 30 h in medium containing SIS3 at the specified
concentrations. (a) Western blotting analysis showing CDA1, phospho-Smad3, and a-tubulin. (b) mRNA levels of TGF-b type I receptor (TbRI)
as determined by real-time PCR in the HK-2 cells. (c, d) Luciferase activities of p3TP-Lux (c) and p(CAGA)12-Luc (d). Before the
adenoviral infection, the HK-2 cells were transfected with the reporter and control plasmids as described in the legend of Figure 5b and
then infected with adenoviruses and treated with SIS3 as described above. (e–g) mRNA levels of collagens I (e), III (f), and IV (g), which were
determined by real-time PCR. Values are means±s.e. s.e. (n¼ 6) is shown as error bar. *Po0.001 vs Ad-Con-infected HK-2 cells; zPo0.01 for
Ad-CDA1 groups treated with SIS3 at 1 vs 0 mM, 5 vs 1 mM, or 10 vs 5 mM.
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METHODS
Antibodies, reagents, and plasmids
Rabbit antibodies to human and mouse CDA1 have been described
previously.9,17 Antibodies to phospho-Smad3 (Ser433/435),
Smad2/3, phospho-ERK1/2 (p42/p44) (Thr202/Tyr204) were from
Cell Signaling Technology (Beverly, MA); antibodies to ERK1/2
(p42/p44) and GAPDH were from Santa Cruz Biotechnology (Santa
Cruz, CA); antibody to a-tubulin was from Sigma-Aldrich (St Louis,
MO); and antibody to a-smooth muscle actin was from Dako
Australia (Campbellfield, Victoria, Australia). Recombinant human
TGF-b1 was from United States Biological (Swampscott, MA). The
TbRI inhibitor, SB431542 was from Tocris Bioscience (Ellisville, MO).
SIS3 was from Sigma-Aldrich. Constructs of p3TP-Lux and
p(CAGA)12-Luc have been described previously.
33,34
Cell culture
The human kidney proximal tubule cell line, HK-2 (CRL-2190), was
from ATCC (Manassas, VA). The human podocyte cell line35 was
a gift from Professor G Camussi and colleagues (University of
Turin, Italy). The stable CDA1 Tet-Off HeLa cell line has been
described previously.9,10 The cells were cultured in DMEM/F12
plus 10% (v/v) fetal bovine serum at 37 1C with 5% CO2. The CDA1
Tet-Off HeLa cells were maintained with 5 ng/ml doxycycline to
switch off the CDA1 transgene, and the doxycycline was withdrawn
from the medium or its concentration was decreased to switch on
the CDA1 transgene to overexpress CDA1.
Retrovirus and adenovirus constructs
The retrovirus expressing hair-pin structured siRNA (m957) to
knockdown CDA1 in both mouse and human cells has been
previously described.10,17 The methods used to prepare the adeno-
virus constructs to overexpress CDA1 or to express hairpin-
structured siRNA to silence CDA1 have been described previously.17
Gene-specific mRNA quantitation
Gene-specific mRNA levels were quantitatively determined using a
PCR system (7500 Fast Real-Time PCR; Applied Biosystems, Foster
City, CA) and normalized against endogenous 18S ribosome
RNA using ribosomal RNA control reagents (TaqMan: Applied
Biosystems). Gene-specific primers and probes used for real-time
reverse transcription-PCR are listed in Supplementary Table S1 online.
Results are shown as fold change (arbitrary unit) relative to control.
Luciferase reporter assay
The luciferase activity assay used to determine the TGF-b signaling
has been described previously.10,17 Briefly, HK-2 cells were
co-transfected by electroporation with pGL3-BASIC, p3TP-Lux or
p(CAGA)12-luc, and cytomegalovirus-b-galactosidase plasmids. The
cells were incubated for 24 h and then treated with TGF-b at
specified concentrations for 30 h. Alternatively, the cells were
infected by adenovirus at specified doses for 24 h, and the medium
was removed and cells were washed before TGF-b treatment for
30 h. Cells were harvested and divided into two halves for measuring
luciferase and b-galactosidase activities, respectively (Luciferase
Assay, E1501; b-Galactosidase Enzyme Assay, E2000; Promega,
Madison, WI). The luciferase activity for each sample was normal-
ized against its b-galactosidase activity.
Animal model
Male SHR at the age of approximately 8 weeks were fasted over-
night and then given a single dose of 45mg/kg streptozotocin
(Boeringer-Mannheim, Mannheim, Germany) by tail-vein injection
to induce diabetes, or given buffer only to serve as non-diabetic
controls.36 Insulin (Ultralente, Novo Industries A/S, Copenhagen,
Denmark) was given to the diabetic rats by subcutaneous injection
at 4U/day. The animals had free access to water and standard rat
chow (Clark King, Melbourne, Australia). Systolic blood pressure
was measured by tailcuff plethysmography in conscious preheated
rats every 4 weeks.37 Urine samples were collected for 24 h in
metabolic cages 1 day before the end of experiment. Blood samples
were collected from conscious rats in order to measure glycated
hemoglobin (HbA1c) before the animals were killed at week 32
after the injection of streptozotocin to induce diabetes, and the
kidneys were collected for histological studies and isolation of
total RNA.
The diabetes-accelerated nephropathy model of ApoE/ mouse
has been previously described.38,39 Briefly, 6-week-old ApoE/
male mice on a C57BL6 background were rendered diabetic by five
daily intraperitoneal injections of streptozotocin at a dose of 55mg/
kg, or given buffer only to serve as non-diabetic controls. Animals
were housed on a 12 h light/dark cycle with free access to water and
standard mouse chow (Specialty Feeds, Glen Forrest, western
Australia, Australia). The animal studies were approved according
to the principles consistent with international guidelines including
the ‘Principles of laboratory animal care’ (National Institutes of
Health, 1985) and the ‘Australian code of practice for the care and
use of animals for scientific purposes’ (National Health and Medical
Council of Australia, 2004). Animals were killed after 20 weeks
of diabetes. Methods for the measurement of HbA1c by high-
performance liquid chromatography and plasma glucose levels have
been described previously.40
IHC, trichrome staining, and human tissue samples
IHC staining for proteins in the paraffin section was described
previously.39 Briefly, after incubation with primary antibodies
(1:1000 dilution for CDA1 and 1:100 for a-smooth muscle actin
antibodies), biotinylated horse anti-rabbit or anti-mouse immuno-
globulin (Vector Laboratories, Burlingame, CA) was used as a
secondary antibody, followed by horseradish peroxidase-conjugated
streptavidin. Peroxidase activity was identified using 3,30-diamino-
benzidine tetrahydrochloride (Sigma Chemical, St Louis, MO).
ECM was stained using Massons’ Trichrome kit (AMT.K) from
Australian Biostain P/L (Traralgon, Victoria, Australia).41 The
positive staining was quantified by assessing approximately 10
random views per section using Image-Pro Plus (Media Cybernetics,
Bethesda, MD). The mean of these data was calculated and used for
analytical comparison between the two groups. Human tissue
samples were provided as gifts from Dr Z Krozowski, which were
derived from histologically normal regions of fresh kidneys of
surgical specimens with appropriate ethic approval as described
previously.42,43
Statistical analysis
T-test was calculated for comparison of two experimental groups.
A P-value o0.05 was considered to be statistically significant.
Data are presented as mean±s.e.m.
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